Obsidian Therapeutics moved toward public-market access through a reverse merger with Galera Therapeutics, with plans to trade on the Nasdaq under ticker OBX. The combined company also secured commitments for a private placement expected to deliver $350 million in gross proceeds. The transaction positions Obsidian to advance oncology-focused programs on a larger funding runway after earlier corporate restructuring steps that left Galera exploring outcomes beyond its original plans. Obsidian’s strategy is anchored in continuing development of its oncology pipeline with the added liquidity from the private placement. For investors and dealmakers, the reverse merger reflects ongoing demand for public-market routes that offer timing and execution certainty relative to traditional IPOs. It also highlights how capital providers are continuing to underwrite oncology innovation through structured market access. The outcome is a fresh data point for how life sciences companies are using alternative capitalization and listings to sustain development momentum in a still-selective IPO environment.